NIH awards Boragen grant for antimalarial drug discovery

By The Science Advisory Board staff writers

July 21, 2020 -- Boron-based discovery platform firm Boragen has received a phase I Small Business Innovation Research grant from the U.S. National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to support antimalarial drug discovery.

Boragen said that the $300,500 grant will further accelerate a collaboration with the University of California, San Francisco that focuses on effective control for Plasmodium, the protozoan parasite that causes malaria.

The project will initially leverage Boragen's boron-based small molecular library to identify new targets and modes of action for inhibiting Plasmodium, according to the company. However, the firm said they are also considering a strategy that could both inhibit the parasite and provide the relevant anti-inflammatory effect.

New drug target identified in malaria transmission
Australian researchers from the University of Melborne and Griffith University in Queensland have confirmed their findings of a new drug target that blocks...
Genomic breakthrough in malaria research
An international consortium of researchers from the Institute of Cell Biology at the University of Bern and Umeå University in Sweden conducted a...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter